Press Room

News / May 23, 2024

Diane Villax receives achievement award at Deloitte´s Investor Relations and Governance Awards (IRGAwards) 2024

36th edition of the Investor Relations & Governance Awards (IRGAwards) promoted by Deloitte

Diane Villax receives achievement award at Deloitte´s Investor Relations and Governance Awards

Diane Villax, Co-Founder and Board Member of Hovione has been honored with a lifetime achievement award at Deloitte´s Investor Relations and Governance Awards (IRGAwards) 2024.

It was especially fitting for her to receive this prestigious award, which recognizes individuals who have made valuable and exceptional contributions to their field, in the year that Hovione celebrates its 65th anniversary.

 

Learn more about IRGAwards

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026